Oppenheimer maintains SPX (NYSE:SPXC) with a Outperform and raises the price target from $72 to $74.
Fusion Pharma Stock Is Trading Higher As FDA Clears Early-Stage Study For Radiopharmaceutical In Neck, Bladder Cancers
The FDA has signed off Fusion Pharmaceuticals Inc’s (NASDAQ:FUSN) Investigational New Drug (IND) applications for [225Ac]-FPI-1966 (FPI-1966) and imaging agent [111In]-FPI-1967…
